11035 Background: ROS1 chromosomal rearrangement (ROS1+) was described as an
oncogenic driver in approximately 1% of non-small cell lung cancers (NSCLC). Due to the …

9078 Background: ROS1 rearrangements are found in approximately 1% of non-small cell
lung cancer (NSCLC) patients. Prospective clinical trials showed high efficacy of crizotinib in …

Background Tyrosine kinase inhibitors (TKIs) are remarkably effective in patients with non-
small cell lung carcinoma (NSCLC) harboring driver gene mutations and rearrangements …

Introduction ROS1 rearrangements are found in 1% of lung cancer patients. Therapeutic
efficacy of crizotinib in this subset has been shown in early phase trials in the United States …

Background Chromosomal rearrangements of the gene encoding ROS1 proto-oncogene
receptor tyrosine kinase (ROS1) define a distinct molecular subgroup of non–small-cell lung …

Background: In the ongoing phase 1 PROFILE 1001 study (NCT00585195), crizotinib
provided a meaningful clinical benefit for patients (pts) with advanced ROS1-rearranged …

8065 Background: Molecular alterations of crizotinib (crz) targets (ALK, MET, ROS1) are
found in a wide range of malignancies. To avoid uncontrolled off-label use and allow for a …

Background In the phase I study PROFILE 1001, crizotinib showed marked antitumor activity
in advanced ROS1-rearranged NSCLC (Shaw, N Engl J Med 2014). We present updated …

Background ROS1 rearrangements are present in the tumors of 1-2% of patients with lung
adenocarcinoma (LAD). This patient subgroup is characterized by non-smoking history and …

Introduction ROS1 rearrangements are seen in 1–2% of non-small cell lung cancer
(NSCLC) patients. The aim of this study was to determine the effectiveness of crizotinib as …